Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature

被引:3
作者
Sampieri, C. L. [1 ]
Orozco-Ortega, R. A. [2 ]
机构
[1] Univ Veracruzana, Inst Salud Publ, Av Luis Castelazo Ayala S-N, Xalapa 91190, Veracruz, Mexico
[2] Univ Veracruzana, Fac Bioanal, Xalapa, Veracruz, Mexico
关键词
Matrix metalloproteinases; tissue inhibitors of metalloproteinases; chronic kidney disease; acute kidney injury; URINARY BIOMARKERS; MATRIX-METALLOPROTEINASE-9; SERUM; STORAGE; DYSREGULATION; DEGRADATION; ZYMOGRAPHY; MORTALITY; MARKER; BLOOD;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases involved in remodeling the extracellular matrix. Tissue inhibitors of metalloproteinases (TIMPs) are a family of four proteins that act to limit the degradative actions of MMPs. Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems worldwide, the prevalence of which has been increasing. Recent concept considers MMPs and TIMPs as critical factors before the onset of microalbuminuria, as well as accelerating factors associated with the breakdown of the glomerular basement membrane, renal scarring, and fibrosis during the progression of kidney diseases. Here we reviewed studies of the expression of MMPs and TIMPs in humans, using as clinical samples serum, plasma, and urine, with a focus on their potential role as molecular markers in CKD and AKI, as non-invasive markers. Material and methods: We used as data sources, studies at Medline database using combinations of the following keywords: CKD, AKI, MMP, TIMP, serum, plasma, and urine. Results: Evidence suggests that MMPs/TIMPs could be potential targets for therapeutic intervention in kidney diseases; future studies should attempt to improve the diagnostic or prognostic power of these families. Discussion: Considering published guides, such as biospecimen reporting for improved study quality (BRISQ), strengthening the reporting of observational studies in epidemiology (STROBE), an updated list of essential items for reporting diagnostic accuracy studies (STARD), transparent reporting of a multivariate prediction model for individual prognosis or diagnosis (TRIPOD), and on the studies reviewed here, we have adapted published recommendations and proposed other news in order to enhance the transparency and quality of MMPs/TIMPs research in CKD and AKI. This review reinforces the complexities of MMPs/TIMPs in the pathobiology of the kidney and the need for well-designed and transparent biomedical studies.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [31] Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis
    Fiedorczyk, Malgorzata
    Klimiuk, Piotr Adrian
    Sierakowski, Stanislaw
    Gindzienska-Sieskiewicz, Ewa
    Chwiecko, Justyna
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (08) : 1523 - 1529
  • [32] Circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with incisional hernia
    Henriksen, Nadia A.
    Sorensen, Lars T.
    Jorgensen, Lars N.
    Agren, Magnus S.
    WOUND REPAIR AND REGENERATION, 2013, 21 (05) : 661 - 666
  • [33] Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids
    Ulrich, Dietmar
    Ulrich, Franziska
    Unglaub, Frank
    Piatkowski, Andrzej
    Pallua, Norbert
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2010, 63 (06) : 1015 - 1021
  • [34] Matrix metalloproteinases in kidney homeostasis and diseases
    Tan, Roderick J.
    Liu, Youhua
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2012, 302 (11) : F1351 - F1361
  • [35] The DNA methylation status of genes encoding Matrix metalloproteinases and tissue inhibitors of Matrix metalloproteinases in endometriosis
    Tang, Longying
    Xiang, Yuqian
    Zhou, Yaohua
    Mu, Jian
    Zai, Meiqing
    Xing, Qinghe
    Zhao, Xinzhi
    He, Lin
    Wang, Lei
    Dong, Xi
    Li, Qiaoli
    MOLECULAR REPRODUCTION AND DEVELOPMENT, 2018, 85 (01) : 17 - 25
  • [36] Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis
    Muehl, Diana
    Nagy, Balint
    Woth, Gabor
    Falusi, Boglarka
    Bogar, Lajos
    Weber, Gyoergy
    Lantos, Janos
    JOURNAL OF CRITICAL CARE, 2011, 26 (06) : 550 - 555
  • [37] Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma
    Yamamoto, H
    Itoh, F
    Adachi, Y
    Fukushima, H
    Itoh, H
    Sasaki, S
    Hinoda, Y
    Imai, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (02) : 58 - 62
  • [38] Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases Ratio: A Biomarker of Bone Resorption in Geriatric Osteoporosis?
    Kanat, Bahar Bektan
    Avci, Gulru Ulugerger
    Bayramlar, Osman Faruk
    Unal, Damla
    Sonmez, Ozge
    Bolayirli, Ibrahim Murat
    Doventas, Alper
    Erdincler, Deniz Suna
    Yavuzer, Hakan
    ANNALS OF GERIATRIC MEDICINE AND RESEARCH, 2023, 27 (02): : 151 - 157
  • [39] Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Echinoderms: Structure and Possible Functions
    Dolmatov, Igor Yu
    Nizhnichenko, Vladimir A.
    Dolmatova, Lyudmila S.
    CELLS, 2021, 10 (09)
  • [40] Fibroblast Growth Factor 23 and Matrix-Metalloproteinases in Patients with Chronic Kidney Disease: Are They Associated with Cardiovascular Disease?
    Peiskerova, M.
    Kalousova, M.
    Kratochvilova, M.
    Dusilova-Sulkova, S.
    Uhrova, J.
    Bandur, S.
    Malbohan, I. M.
    Zima, T.
    Tesar, V.
    KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (04) : 276 - 283